Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BST08 in Advanced Non-Small Cell Lung Cancer
NCT06643910Phase 1Not yet recruiting
- Sponsor
- Biosyngen
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BST08 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Biosyngen. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
BST08
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06643910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643910.